Physician profile
Morris Silver
NPI 1871546127
$40,264.50
in general payments reported to CMS, 2019-2025
25 companies · $10K in 2025
The $10K reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.52 · 2020: $409 · 2021: $1,059 · 2022: $1,209 · 2023: $2,279 · 2024: $25K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $6,874 · Consulting Fee: $783 · Travel and Lodging: $99.67 · Education: $73.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,670.00 |
| Food and Beverage | $6,874.23 |
| Consulting Fee | $783.34 |
| Travel and Lodging | $99.67 |
| Education | $73.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30,517.51 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,616.52 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,595.12 | 2020-2025 | Rinvoq, Skyrizi |
| Vertex Pharmaceuticals Incorporated | $783.34 | 2023 | |
| Redhill Biopharma INC. | $535.55 | 2020-2025 | Talicia, Movantik, Aemcolo |
| Genzyme Corporation | $525.32 | 2023-2025 | |
| Qol Medical, LLC | $505.18 | 2020-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $477.92 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $430.78 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $363.17 | 2021-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $224.63 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $172.66 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $84.70 | 2019-2023 | Rebyota, Clenpiq |
| Madrigal Pharmaceuticals | $81.74 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $81.09 | 2023-2024 | Linzess |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $65.41 | 2023 | |
| Nestle Healthcare Nutrition INC. | $64.05 | 2022-2023 | |
| Braintree Laboratories, INC. | $53.32 | 2019 | |
| Novo Nordisk INC | $29.57 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.81 | 2023 | Cyltezo |
| Celgene Corporation | $19.28 | 2024 | Zeposia |
| Azurity Pharmaceuticals, INC. | $17.83 | 2025 | Suflave |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$480,200.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.